

Special Issue

Heart Failure: From Subtype to Personalized Medicine

Message from the Guest Editor

Heart failure (HF) is a major social problem that has been increasing in its prevalence worldwide due to a rapidly aging society. Even though recent progress in the understanding of the pathology of HF and certain forms of cardiomyopathies (e.g. amyloidosis, Fabry disease) has enabled the development of novel diagnostic and management strategies, their prognosis has not yet been satisfactory. Newly recognized cardiovascular disease entities have emerged as new problems. There have been limited therapeutics for heart failure with preserved ejection fraction (HFpEF). Recent advances in cancer therapy have improved life expectancy for cancer patients, but instead survivors often are left suffering from cardiovascular complications such as cancer therapeutics-related cardiac dysfunction (CTRCD). The current devastating COVID-19 outbreak might cause various cardiovascular complications, such as myocarditis and thrombosis, for some affected patients. However, cardioprotective strategies for these emerging diseases have not yet been established. This Special Issue aims to highlight the current knowledge and future perspectives potentially leading to novel personalized approaches to HF.

Guest Editor

Dr. Yuji Nagatomo

Department of Cardiology, National Defense Medical College,
Tokorozawa, Saitama 359, Japan

Deadline for manuscript submissions

closed (10 October 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/156352

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).